As communities continue to be impacted by COVID-19, we are a reliable source for people in search of answers. We are working closely with our infectious disease experts, other health care entities, and federal, state, and local agencies to ensure our information is accurate and up to date.
Projects of the Center for Clinical and Translational Sciences include several initiatives to address testing disparities in vulnerable and underserved populations across the state, including in the Houston metro area, in South Texas, and in East Texas and West Texas, which have higher rates of uninsured and African American populations.
More than a year after COVID-19 sent her to the hospital for seven days, which included treatment with low amounts of supplemental oxygen, Sophia Holton is still suffering symptoms from the virus: headaches, pain, shortness of breath, and low energy.
A nasal therapy, built upon on the application of a new engineered IgM antibody therapy for COVID-19, was more effective than commonly used IgG antibodies at neutralizing the COVID-19 virus in animal models, according to research recently published by The University of Texas Health Science Center at Houston (UTHealth), The University of Texas Medical Branch at Galveston (UTMB Health), the University of Houston, and IGM Biosciences, Inc.
Pregnant women who are hospitalized with COVID-19 and viral pneumonia are less likely than non-pregnant women to die from these infections, according to a new study by researchers with The University of Texas Health Science Center at Houston (UTHealth) and the University of Maryland School of Medicine (UMSOM).
A large national clinical trial to evaluate the Pfizer-BioNTech COVID-19 vaccine for safety and efficacy in pregnant women is now open for enrollment at The University of Texas Health Science Center at Houston (UTHealth).
Researchers are using a novel health platform that links them to shared electronic health records from consented patients to track long-term effects of COVID-19 in a new study by UTHealth.
A $4 million subcontract grant for scientists to collect COVID-19 data from virus researchers across the country in order to develop a data coordinating center has been awarded to researchers at The University of Texas Health Science Center at Houston (UTHealth) School of Biomedical Informatics.
Researchers at The University of Texas Health Science Center at Houston (UTHealth) and The University of Texas Medical Branch at Galveston (UTMB Health) have discovered a potential new antibody therapy for COVID-19. The study was published in Nature Communications.
Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients were awarded $5.1 million in funding from the U.S. Department of Defense (DOD) to expand the Phase II clinical trial at UTHealth.
Neurologists are researching whether a novel immunomodulatory treatment, OP-101, can dampen lung and brain injury in hospitalized COVID-19 patients through a clinical trial at The University of Texas Health Science Center at Houston (UTHealth).
